Your Feed

Filter by
See content from
Back to the latest
Avatar
Kneyed
Multiple Myeloma Discussion • December 15, 2024
I’m just starting my remission maintenance regime after 7 cycles of induction RVD+Dara. Feeling very
I’m just starting my remission maintenance regime after 7 cycles of induction RVD+Dara. Feeling very grateful about the progress this past year. Question does everyone usually get to continue the lower dose 10mg Revlimid for 21 day cycle or 30 days continuously? I’ll be getting one shot of DarZalex a month too hopefully 🙏🏼 Awaiting the results of my scans + BMB. Blessings and Good Health everyone 💪🪧
Avatar
KooGS123
Multiple Myeloma Discussion • December 14, 2024
Managing Bone Disease: Seeking Recommendations?
AI-generated title
Hi Everyone, I'm two months past a stem cell transplant, doing well energetically, in remission. However I have a lot of bone disease in my spine, ribs and sternum, really bad (I've lost 6" in height). I am getting zometa, taking supplements, doing exercises. Can anyone recommend a hospital, doctor or PT program that specializes in dealing with bone disease from myeloma? Thanks.
Avatar
alexandra.sazonova.prokouran@gmail.com
Multiple Myeloma Discussion • December 14, 2024
Managing Denosumab ONJ: Treatment and Pain?
AI-generated title
Hi friends, Does anyone have experience with osteonecrosis of the jaw (ONJ) caused by denosumab? What treatments have been most effective for managing early-to-medium stage ONJ? Also, how do you deal with the pain associated with it? Thank you so much in advance🙏🏼
Thumbnail for MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24
Playlist: ASH 2024

MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24

Video details & playlist
Avatar
ChioOsuna
Multiple Myeloma Discussion • December 13, 2024
Your HealthTree Data Made an Impact at ASH
AI-generated title
At ASH this year, researchers presented groundbreaking data from collaborative studies with HealthTree. Your participation in Cure Hub made this possible, showcasing the power of real-world data in driving meaningful advancements in care and research. Thank you for being an essential part of this progress! #ASH24 #HealthTree #PatientAdvocacy #InnovationThatSavesLives #ASHMeeting #Hematology #BloodCancer #MedicalResearch #CancerCare #ASH2024
Thumbnail for Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24
Playlist: ASH 2024

Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24

Video details & playlist
Avatar
ChioOsuna
Multiple Myeloma Discussion • December 13, 2024
Celebrating Patient Impact at ASH24
AI-generated title
✨ Every breakthrough, every discovery, every step forward at #ASH24 began with YOU! As we wrap up another groundbreaking ASH Annual Meeting, we're reminded that behind every clinical trial, and every presentation stands a patient and their family who made it all possible. Watch as leading experts acknowledge the true heroes of blood cancer research - the patients who generously give their time, share their experiences, and participate in studies that push us closer to a cure. At HealthTree, we're committed to amplifying your voice and ensuring patients remain at the heart of research. Together, we're not just witnessing the future of blood cancer treatment - we're helping create it. #BloodCancer #CancerResearch #ASH24 #HealthTree #CancerCommunity #HopeForCures
Thumbnail for Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24
Playlist: ASH 2024

Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24

Video details & playlist
Thumbnail for Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24
Playlist: ASH 2024

Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24

Video details & playlist
Thumbnail for Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24
Playlist: ASH 2024

Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24

Video details & playlist
Thumbnail for Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24
Playlist: ASH 2024

Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24

Video details & playlist
Thumbnail for The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24
Playlist: ASH 2024

The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24

Video details & playlist
Thumbnail for Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24
Playlist: ASH 2024

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24

Video details & playlist
Thumbnail for Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24
Playlist: ASH 2024

Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24

Video details & playlist
Thumbnail for Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24
Playlist: ASH 2024

Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24

Video details & playlist
Thumbnail for Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24
Playlist: ASH 2024

Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24

Video details & playlist
Thumbnail for Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24
Playlist: ASH 2024

Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24

Video details & playlist
Thumbnail for Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24
Playlist: ASH 2024

Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24

Video details & playlist
Thumbnail for Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24
Playlist: ASH 2024

Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24

Video details & playlist